SB
TVRD

Strategic Blueprint’s Tvardi Therapeutics TVRD Stock Holding History

Strategic Blueprint’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3
Closed -$1K – 1371
2021
Q2 		$1K Buy
+3
New +$1.9K ﹤0.01% 1385

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Strategic Blueprint's TVRD Position: Q3 2021 in Review

Strategic Blueprint sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 3 shares — an estimated $1K sold.

Strategic Blueprint first reported a position in TVRD in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • Strategic Blueprint reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Strategic Blueprint sold 3 Tvardi Therapeutics shares in Q3 2021, an estimated $1K.
  • Strategic Blueprint first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 1 quarter.
  • Strategic Blueprint's Tvardi Therapeutics position peaked at $1K in Q2 2021.
  • 169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.